Foundation Medicine / Acolin Fund Services AG / Checkpoint / Bank Julius Bär Europe AG / Abbott / Bellevue Asset Management AG / Sparkassen AG / Intrexon / Bellevue Funds / Erste Bank / Medtronic / Adamant Biomedical Investment AG / LabCorp / Bellevue AG / Kite / M. The Bellevue Funds / Bloomberg / BB Funds / Bluebird / Bristol-Myers Squibb / CONTACT Bellevue Asset Management AG / Stefan Blum / /
Country
Switzerland / Germany / Austria / United States / Luxembourg / /
Currency
CHF / USD / EUR / /
Event
Business Partnership / M&A / Funding / /
IndustryTerm
test systems / biotechnology / Cancer therapies / automation offering products / analytical devices / pharmaceutical / healthcare sector / particular patient / medical technology / personalized therapies but with different technologies / healthcare industry / gene sequencing technology / pure biotechnology fund / health insurance providers / financial product / medical technology stocks / therapy for the treatment of hereditary metabolic disorders / laboratory equipment / diagnostic tool / /
MedicalCondition
common cancers / hemophilia / leukemia / tumor / hereditary metabolic disorders / hereditary diseases / cancer / body’s natural cancer / disease / solid tumor / tumor cell / hepatitis C. Another / genetic diseases / biotechnologically developed cancer / diseases / /
In Focus May 2015 Personalized medicine offers blockbuster potential